Reuters logo
BRIEF-GSK says BCMA receives FDA breakthrough therapy designation and orphan drug designation
November 2, 2017 / 7:44 AM / 15 days ago

BRIEF-GSK says BCMA receives FDA breakthrough therapy designation and orphan drug designation

Nov 2 (Reuters) - GLAXOSMITHKLINE PLC

* BCMA RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION

* ‍INVESTIGATIONAL BCMA ANTIBODY-DRUG CONJUGATE RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM US FDA FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA​

* ‍GSK2857916 HAS ALSO RECEIVED ORPHAN DRUG DESIGNATION FROM EMA AND FDA FOR MULTIPLE MYELOMA​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below